Small molecule · Inhibitor of ErbB receptor tyrosine kinases (EGFR family) · developed by Sunshine Lake Pharma Co.
Larotinib is an oral reversible pan-ErbB tyrosine kinase inhibitor that binds and inhibits ErbB receptors, the EGFR family. It is studied in esophageal cancer and advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04415853 | Phase 3 | Esophageal Cancer | Recruiting | SBFM |
| NCT05048368 | Phase 1 | Esophageal Cancer | Withdrawn | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Esophageal CancerAdvanced Solid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →